Disc Medicine
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 74
- Market Cap
- -
- Website
- http://www.discmedicine.com
- Introduction
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. The company was founded in October 2017 and is headquartered in Watertown, MA.
Disc Medicine Advances Bitopertin NDA for Erythropoietic Protoporphyria as Pipeline Progress Continues
Disc Medicine has initiated the APOLLO confirmatory trial for bitopertin in erythropoietic protoporphyria (EPP) and remains on track to submit an NDA under accelerated approval pathway in the second half of 2025.
Alterity Therapeutics Secures A$40M Funding to Accelerate MSA Drug Development
Alterity Therapeutics has raised A$40 million through a two-tranche placement to advance ATH434, their lead compound showing promising results in Multiple System Atrophy treatment.
FDA Aligns with Gemini Therapeutics on APOLLO Trial Design for Bitopertin in Rare Porphyria Disorders
Gemini Therapeutics has successfully concluded a Type C meeting with the FDA, reaching agreement on the design of APOLLO confirmatory trial for bitopertin in EPP and XLP treatment.
Disc Medicine Advances Hematology Pipeline with Bitopertin NDA Plans and Phase 2 Trials
Disc Medicine is preparing for an NDA submission for bitopertin in erythropoietic protoporphyria (EPP) following positive FDA feedback, potentially leading to accelerated approval.
Alterity Therapeutics' ATH-434 Shows Promise in Slowing Multiple System Atrophy
Alterity Therapeutics' ATH-434 demonstrated statistically significant slowing of clinical progression in early-stage multiple system atrophy (MSA) patients.
Disc Medicine's DISC-0974 Shows Positive Results in Myelofibrosis Phase 1b Trial
Disc Medicine presented Phase 1b trial results of DISC-0974 for myelofibrosis-associated anemia at the ASH annual meeting, showing significant clinical benefits.
Disc Medicine Secures $200M to Advance Clinical Trials of Hematologic Disease Therapies
Disc Medicine has obtained a $200 million non-dilutive term loan to support its clinical trials and enhance financial flexibility.
Disc Medicine's Bitopertin Poised for Potential Accelerated FDA Approval in Erythropoietic Protoporphyria
Disc Medicine's bitopertin may receive accelerated FDA approval for erythropoietic protoporphyria (EPP) treatment based on existing clinical data.
Disc Medicine's Bitopertin Gains Momentum with Positive Regulatory Feedback and Analyst Upgrades
Disc Medicine received positive feedback from the FDA regarding bitopertin for erythropoietic protoporphyria (EPP), potentially allowing for accelerated approval based on PPIX reduction.
Disc Medicine Gains FDA Alignment on Bitopertin Trial Design for Erythropoietic Protoporphyria
Disc Medicine's Type C meeting with the FDA resulted in alignment on the design of the APOLLO post-marketing confirmatory trial for bitopertin in EPP.